- Home
- EPSM vs VERU Comparison
EPSM vs VERU Comparison
Compare EPSM & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EPSM | VERU |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6M | 39.8M |
| IPO Year | 2025 | 1990 |
Fundamental Metrics
Financial Performance| Metric | EPSM | VERU |
|---|---|---|
| Price | $2.64 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 3.6M | 108.8K |
| Earning Date | 12-05-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,446,963.00 | ★ $16,886,419.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 337.24 |
| 52 Week Low | $1.31 | $2.11 |
| 52 Week High | $155.00 | $14.20 |
Technical Indicators
Market Signals| Indicator | EPSM | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 32.18 | 40.04 |
| Support Level | $2.43 | $2.33 |
| Resistance Level | $4.00 | $2.70 |
| Average True Range (ATR) | 0.46 | 0.15 |
| MACD | 0.68 | 0.05 |
| Stochastic Oscillator | 6.96 | 42.86 |
Price Performance
Historical ComparisonAbout EPSM Epsium Enterprise Limited Ordinary Shares
Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.